Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 2/20 | 0.38 |
| ▸ | RET | P07949 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | RXRA | P19793 | 1/20 | 0.35 |
| ▸ | RXRB | P28702 | 1/20 | 0.35 |
| ▸ | RXRG | P48443 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | TP53 | P04637 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.33 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | XDH | P47989 | 1/20 | 0.32 |
| ▸ | ELANE | P08246 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14658464 | 0.91 | ATR (0.36) | ATRRETRXRARXRBRXRG | |
| SCHEMBL29502036 | 0.91 | ATR (0.36) | ATRRETRXRARXRBRXRG | |
| SCHEMBL30182911 | 0.84 | MAPT (0.38) | ATRRETSMN1; SMN2RXRARXRB | |
| SCHEMBL25473050 | 0.83 | ATR (0.36) | ATRRETRXRARXRBRXRG | |
| SCHEMBL19204829 | 0.83 | ELANE (0.43) | ATRRETMAPTALDH1A1MAPK1 | |
| SCHEMBL29167963 | 0.83 | ELANE (0.34) | MAPTELANECTSK | |
| SCHEMBL29959666 | 0.83 | ELANE (0.43) | ATRRETMAPTALDH1A1MAPK1 | |
| SCHEMBL30673140 | 0.82 | RET (0.34) | RETSMN1; SMN2RXRARXRBRXRG | |
| SCHEMBL26924343 | 0.82 | RET (0.34) | RETSMN1; SMN2RXRARXRBRXRG | |
| SCHEMBL767404 | 0.81 | CYP4F2 (0.39) | ATRRETSMN1; SMN2RXRARXRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260069571-A1 | DDR1 AND DDR2 INHIBITORS FOR THE TREATEMENT OF CANCER AND FIBROTIC DISEASES | REDX PHARMA PLC (GB) | 2026-03-12 | — | — | US | disclosed |
| EP-4426688-B1 | DDR1 AND DDR2 INHIBITORS FOR THE TREATEMENT OF CANCER AND FIBROTIC DISEASES | REDX PHARMA LTD (GB) | 2025-12-03 | — | — | EP | disclosed |
| EP-4426688-A1 | DDR1 AND DDR2 INHIBITORS FOR THE TREATEMENT OF CANCER AND FIBROTIC DISEASES | Redx Pharma Plc (GB) | 2024-09-11 | — | — | EP | disclosed |
| CN-118201918-A | DDR1 and DDR2 inhibitors for the treatment of cancer and fibrotic diseases | 莱德克斯制药公共有限公司 | 2024-06-14 | — | — | CN | disclosed |
| WO-2023079291-A1 | DDR1 AND DDR2 INHIBITORS FOR THE TREATEMENT OF CANCER AND FIBROTIC DISEASES | REDX PHARMA PLC (GB) | 2023-05-11 | — | — | WO | disclosed |
| US-8378104-B2 | 7-aminofuropyridine derivatives | OSI Pharmaceuticals, LLC (US) | 2013-02-19 | — | — | US | disclosed |
| US-20120046267-A1 | 7-AMINOFUROPYRIDINE DERIVATIVES | OSI PHARMACEUTICALS, INC. | 2012-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046267-A1 | 7-AMINOFUROPYRIDINE DERIVATIVES | MAP3K5, STK17A, MAPKAPK5 | ATR 1630/4885RET 588/4885SMN1; SMN2 1807/4885 |
| US-20260069571-A1 | DDR1 AND DDR2 INHIBITORS FOR THE TREATEMENT OF CANCER AND FIBROTIC DISEASES | DDR1, DDR2, TGFBR2 | ATR 457/4885RET 300/4885SMN1; SMN2 1766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.